Is Cue Biopharma, Inc. (CUE) a Buy, Sell, or Hold?
NASDAQ : CUE
Cue Biopharma, Inc.
$28.4 USD
-$0.09 (-0.32%)
- Volume
- 14.34K
- Average Volume
- 583.16K
- Market Capitalization
- $74.63M
- P/E Ratio
- -4.88
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $45.50
- Year Low
- $4.98
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.57
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
32
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
0
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
-$
CUE Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
CUE Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Borie Dominique Christian | officer, other: Chief Medical Officer | 2026-07-13 | A-Award | 30.92 | 2026-07-15 |
| Borie Dominique Christian | officer, other: Chief Medical Officer | 2026-07-13 | A-Award | 0 | 2026-07-15 |
| Borie Dominique Christian | 2026-07-13 | 0 | 2026-07-15 | ||
| Garzone Pamela | director | 2026-07-09 | A-Award | 0 | 2026-07-10 |
| Camardo Daniel A. | director | 2026-07-09 | A-Award | 0 | 2026-07-10 |
| Sarraf Pasha | director | 2026-07-09 | A-Award | 0 | 2026-07-10 |
| Meehan Viola Mong | director | 2026-07-09 | A-Award | 0 | 2026-07-10 |
| Meluzio Michael Vincent | officer: VP, Prin. Accounting Officer | 2026-07-09 | A-Award | 0 | 2026-07-10 |
| Ray Sumita | officer, other: Chief Legal Compliance Officer | 2026-07-09 | A-Award | 0 | 2026-07-10 |
| Ray Sumita | officer, other: Chief Legal Compliance Officer | 2026-07-09 | A-Award | 0 | 2026-07-10 |
| Lin Shao-Lee | director, officer: Chief Executive Officer | 2026-07-09 | A-Award | 0 | 2026-07-10 |
| Lin Shao-Lee | director, officer: Chief Executive Officer | 2026-07-09 | A-Award | 0 | 2026-07-10 |
| Meluzio Michael Vincent | 2026-06-01 | 0 | 2026-06-11 | ||
| Ray Sumita | officer, other: Chief Legal Compliance Officer | 2026-06-01 | 0 | 2026-06-11 | |
| Ray Sumita | officer, other: Chief Legal Compliance Officer | 2026-06-01 | 30.42 | 2026-06-11 | |
| Camardo Daniel A. | director | 2026-05-30 | A-Award | 21.9 | 2026-06-08 |
| Camardo Daniel A. | 2026-05-30 | 0 | 2026-06-08 | ||
| Lin Shao-Lee | director, officer: Chief Executive Officer | 2026-06-01 | P-Purchase | 0.001 | 2026-06-03 |
| Lin Shao-Lee | director, officer: Chief Executive Officer | 2026-06-01 | P-Purchase | 11 | 2026-06-03 |
| Meehan Viola Mong | director | 2026-05-30 | A-Award | 21.9 | 2026-06-02 |
| Meehan Viola Mong | 2026-05-30 | 0 | 2026-06-02 | ||
| Lin Shao-Lee | 2026-04-30 | 0 | 2026-05-07 | ||
| Lin Shao-Lee | director, officer: CHIEF EXECUTIVE OFFICER | 2026-05-03 | A-Award | 30.42 | 2026-05-07 |
| Lin Shao-Lee | director, officer: CHIEF EXECUTIVE OFFICER | 2026-05-03 | A-Award | 0 | 2026-05-07 |
| Sandercock Colin | officer: SVP, GENERAL COUNSEL | 2026-04-09 | A-Award | 0.29 | 2026-04-10 |
| Warren Lucinda | officer: CHIEF BUSINESS OFFICER | 2026-04-09 | A-Award | 0.29 | 2026-04-10 |
| Baker Daniel G. | officer: CHIEF DEVELOPMENT OFFICER | 2026-04-09 | A-Award | 0.29 | 2026-04-10 |
| Kiener Peter A | director | 2026-01-02 | A-Award | 0.34 | 2026-01-06 |
| Broadfoot Jill Marie | director | 2026-01-02 | A-Award | 0.34 | 2026-01-06 |
| Garzone Pamela | director | 2026-01-02 | A-Award | 0.34 | 2026-01-06 |
| Morich Frank | director | 2026-01-02 | A-Award | 0.34 | 2026-01-06 |
| Verheyen Patrick | director | 2026-01-02 | A-Award | 0.34 | 2026-01-06 |
| Sarraf Pasha | director | 2026-01-02 | A-Award | 0.34 | 2026-01-06 |
| Sarraf Pasha | director | 2025-12-30 | P-Purchase | 0.3016 | 2026-01-02 |
| Sarraf Pasha | director | 2025-12-30 | P-Purchase | 0.3114 | 2026-01-02 |
| Sarraf Pasha | director | 2025-12-30 | P-Purchase | 0.3174 | 2026-01-02 |
| Sarraf Pasha | director | 2025-12-30 | P-Purchase | 0.3003 | 2026-01-02 |
| Sarraf Pasha | director | 2025-12-30 | P-Purchase | 0.3094 | 2026-01-02 |
| Sandercock Colin | officer: SVP, GENERAL COUNSEL | 2025-12-03 | A-Award | 0.7 | 2025-12-05 |
| Sandercock Colin | officer: SVP, GENERAL COUNSEL | 2025-09-26 | A-Award | 0.7 | 2025-12-05 |
| Warren Lucinda | officer: CHIEF BUSINESS OFFICER | 2025-09-29 | A-Award | 0.72 | 2025-11-25 |
| Baker Daniel G. | officer: CHIEF DEVELOPMENT OFFICER | 2025-09-29 | A-Award | 0.72 | 2025-11-25 |
| Azam Usman | director, officer: CHIEF EXECUTIVE OFFICER | 2025-09-29 | A-Award | 0.72 | 2025-10-02 |
| Azam Usman | 2025-09-29 | 0 | 2025-10-02 | ||
| Broadfoot Jill Marie | director | 2025-06-04 | A-Award | 0.62 | 2025-06-06 |
| Broadfoot Jill Marie | 2025-06-04 | 0 | 2025-06-06 | ||
| Millar Kerri-Ann | officer: CHIEF FINANCIAL OFFICER | 2025-03-21 | A-Award | 0.99 | 2025-03-25 |
| PASSERI DANIEL R | director, officer: CHIEF EXECUTIVE OFFICER | 2025-03-21 | A-Award | 0.99 | 2025-03-25 |
| Baker Daniel G. | officer: CHIEF DEVELOPMENT OFFICER | 2025-03-21 | A-Award | 0.99 | 2025-03-25 |
| Sandercock Colin | officer: SVP, GENERAL COUNSEL | 2025-03-21 | A-Award | 0.99 | 2025-03-25 |
| Warren Lucinda | officer: CHIEF BUSINESS OFFICER | 2025-03-21 | A-Award | 0.99 | 2025-03-25 |
| Levisetti Matteo | officer: Chief Medical Officer | 2025-03-21 | A-Award | 0.99 | 2025-03-25 |
| Sarraf Pasha | director | 2025-03-10 | A-Award | 1.03 | 2025-03-12 |
| Sarraf Pasha | 2025-03-10 | 0 | 2025-03-12 | ||
| Verheyen Patrick | director | 2025-01-02 | A-Award | 1.09 | 2025-01-03 |
| Garzone Pamela | director | 2025-01-02 | A-Award | 1.09 | 2025-01-03 |
| Morich Frank | director | 2025-01-02 | A-Award | 1.09 | 2025-01-03 |
| DRISCOLL FREDERICK W | director | 2025-01-02 | A-Award | 1.09 | 2025-01-03 |
| Kiener Peter A | director | 2025-01-02 | A-Award | 1.09 | 2025-01-03 |
| PASSERI DANIEL R | director, officer: CHIEF EXECUTIVE OFFICER | 2024-12-16 | P-Purchase | 1.03 | 2024-12-18 |
| Baker Daniel G. | officer: CHIEF DEVELOPMENT OFFICER | 2024-11-25 | A-Award | 1.06 | 2024-11-29 |
| Baker Daniel G. | 2024-11-25 | 0 | 2024-11-29 | ||
| Warren Lucinda | 2024-09-03 | 0 | 2024-09-05 | ||
| Warren Lucinda | officer: CHIEF BUSINESS OFFICER | 2024-09-03 | A-Award | 0.66 | 2024-09-05 |
| Levisetti Matteo | officer: Chief Medical Officer | 2024-06-05 | A-Award | 1.65 | 2024-06-07 |
| Suri Anish | officer: PRESIDENT AND CSO | 2024-06-05 | A-Award | 1.65 | 2024-06-07 |
| Fox Michael J | director | 2024-06-05 | A-Award | 1.65 | 2024-06-07 |
| Sandercock Colin | officer: SVP, GENERAL COUNSEL | 2024-06-05 | A-Award | 1.65 | 2024-06-07 |
| Fox Michael J | director | 2024-06-05 | 0 | 2024-06-07 | |
| Fox Michael J | director | 2024-06-05 | 0 | 2024-06-07 | |
| Millar Kerri-Ann | officer: CHIEF FINANCIAL OFFICER | 2024-06-05 | A-Award | 1.65 | 2024-06-07 |
| Sandercock Colin | officer: SVP, GENERAL COUNSEL | 2024-03-06 | A-Award | 1.94 | 2024-03-08 |
| Suri Anish | officer: PRESIDENT AND CSO | 2024-03-06 | A-Award | 1.94 | 2024-03-08 |
| Millar Kerri-Ann | officer: CHIEF FINANCIAL OFFICER | 2024-03-06 | A-Award | 1.94 | 2024-03-08 |
| PASSERI DANIEL R | director, officer: CHIEF EXECUTIVE OFFICER | 2024-03-06 | A-Award | 1.94 | 2024-03-08 |
| Levisetti Matteo | officer: Chief Medical Officer | 2024-03-06 | A-Award | 1.94 | 2024-03-08 |
| Levisetti Matteo | officer: Chief Medical Officer | 2024-02-20 | A-Award | 3.36 | 2024-02-22 |
| Garzone Pamela | director | 2024-01-02 | A-Award | 2.78 | 2024-01-04 |
| Kiener Peter A | director | 2024-01-02 | A-Award | 2.78 | 2024-01-04 |
| DRISCOLL FREDERICK W | director | 2024-01-02 | A-Award | 2.78 | 2024-01-04 |
| Verheyen Patrick | director | 2024-01-02 | A-Award | 2.78 | 2024-01-04 |
| Morich Frank | director | 2024-01-02 | A-Award | 2.78 | 2024-01-04 |
| Suri Anish | officer: PRESIDENT AND CSO | 2023-08-25 | P-Purchase | 2.76 | 2023-08-29 |
| PASSERI DANIEL R | director, officer: CHIEF EXECUTIVE OFFICER | 2023-08-14 | P-Purchase | 2.86 | 2023-08-16 |
| Levisetti Matteo | officer: Chief Medical Officer | 2023-07-21 | A-Award | 4.2 | 2023-07-25 |
| Millar Kerri-Ann | officer: CHIEF FINANCIAL OFFICER | 2023-07-21 | A-Award | 4.2 | 2023-07-25 |
| PASSERI DANIEL R | director, officer: CHIEF EXECUTIVE OFFICER | 2023-07-21 | A-Award | 4.2 | 2023-07-25 |
| Sandercock Colin | officer: SVP, GENERAL COUNSEL | 2023-07-21 | A-Award | 4.2 | 2023-07-25 |
| Suri Anish | officer: PRESIDENT AND CSO | 2023-07-21 | A-Award | 4.2 | 2023-07-25 |
| Garzone Pamela | director: | 2023-04-19 | 0 | 2023-04-25 | |
| Garzone Pamela | director | 2023-04-19 | A-Award | 3.46 | 2023-04-21 |
| Verheyen Patrick | director | 2023-04-11 | 0 | 2023-04-13 | |
| Verheyen Patrick | director | 2023-04-11 | A-Award | 3.11 | 2023-04-13 |
| Kiener Peter A | director | 2023-03-23 | M-Exempt | 2.86 | 2023-03-27 |
| Kiener Peter A | director | 2023-03-23 | M-Exempt | 2.86 | 2023-03-27 |
| Kiener Peter A | director | 2023-03-23 | S-Sale | 3.28 | 2023-03-27 |
| NASSHORN PATRICIA | officer: Chief Business Officer | 2023-02-16 | A-Award | 3.21 | 2023-02-21 |
| Suri Anish | officer: PRESIDENT AND CSO | 2023-02-16 | A-Award | 3.21 | 2023-02-21 |
| Sandercock Colin | officer: SVP, GENERAL COUNSEL | 2023-02-16 | A-Award | 3.21 | 2023-02-21 |
| PASSERI DANIEL R | director, officer: CHIEF EXECUTIVE OFFICER | 2023-02-16 | A-Award | 3.21 | 2023-02-21 |